Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1043580

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1043580

Global Skin Cancer Drugs Market - 2021-2028

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

The Global Skin Cancer Drugs Market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX% during the forecast period (2021-2028).

Skin Cancer Drugs is the most common type of cancer caused due to abnormal growth of skin cells. It is estimated that 90% of skin cancer drugs is caused majorly due to solar and artificial ultraviolet radiation (UV). The drug's use for the treatment of skin cancer is called skin cancer drugs. There are many drugs available in the market for the treatment of skin cancer.

Market Dynamics

The global skin cancer drugs market growth is driven by the increasing incidence of skin cancer, extensive R&D pipelines, and rising awareness about skin cancer.

Strong emerging pipeline for the treatment of skin cancer will drive the market growth

Strong emerging pipeline for skin cancer drugs is expected to drive the market over the forecast period. Merck & Co, Inc, announced its phase 3 KEYNOTE-716 (NCT03553836) trial investigating pembrolizumab (Keytruda) has met its primary end point of recurrence-free survival (RFS) for the treatment of patients with surgically removed stage II melanomas. Based on that data, the FDA has accepted a new supplemental biologics license application (sBLA) for pembrolizumab to treat patients 12 aged years or older with stage IIB or IIC melanoma following removal and has set a Prescription Drug User Fee Act (PDUFA).

The FDA has given fast track designation for nemvaleukin alfa an investigational engineered interleukin (IL) variant immunotherapy, for the treatment of mucosal melanoma. This comes after the FDA granted orphan drug designation to nemvaleukin alfa for the treatment of mucosal melanoma. Thus many drugs for the treatment of skin cancer is approved by FDA.

This will lead to the introduction of novel drugs that will transform this previous stagnant market and will improve treatment options for patients. Mainly, treatment strategies for specific patient subsets have shifted towards more-targeted treatments. Evidence from late-stage melanoma pipeline indicates that this trend is going to continue. Research and development have gained a lot of attention in the past few decades of skin cancer treatment due to rapidly increasing incident cases. More numbers of clinical trials have been investigated to find an effective therapeutics with high safety and efficacy levels.

Some more recent drug approvals like the targeted therapies Tafin that was also approved for BRAF-positive melanoma, and immune checkpoint inhibitors Keytruda (pembrolizumab) and Opdivo (nivolumab). Amplimexon of Amplimed is phase 2 stage of development. Aside from Onxeo is in phase 1 clinical trials. Other products like Trilexium of Kazia is preclinically developed now. These factors will drive the growth of the market in the forecast period.

Complications related to chemotherapy is likely to hamper the market growth

However, chemotherapy drugs use in the treatment of skin cancer can treats the disease effectively. But like other treatments, it often causes side effects. The side effects of chemotherapy are different for each person. They depend on the type of cancer, location, drugs and dose, and general health. But because these drugs travel throughout the body, they can affect normal, healthy cells that are fast-growing, too. Damage to healthy cells causes side effects.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the skin cancer drugs market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types including skin cancer. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the skin cancer drugs market.

Segment Analysis

Non-melanoma segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Non-melanoma is expected to hold a significant market share in the cancer type. Currently, around 2-3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. According to the World Cancer Research Fund International, in 2018, non-melanoma skin cancer is the fifth most commonly occurring cancer in people, with over one million diagnosis worldwide. Thus, it is the most common malignancy in the United States, with substantial associated morbidity and cost, as well as relatively small but significant mortality.

According to Cancer Research UK, there are around 147,000 new non-melanoma skin cancer cases in the United Kingdom every year, which is more than 400 every day (2014-2016). In 2016, around 67,700 new cases in females and 88,700 new cases in males have been registered.

Treatment for non-melanoma skin cancer is usually successful, as unlike the other types of cancer, there's a significantly lower risk that the cancer will spread to other parts of the body. Treatment for non-melanoma skin cancer is completely successful in approximately 90% of cases. Hence, the increasing rates of the non-melanoma skin cancer and its successful rates after treatment will drive the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share of global skin cancer drugs market

North America is expected to dominate the market in the forecast period. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Furthermore, as per the estimates of the American Cancer Society, in 2018, there were around 91,270 new cases of melanoma in the United States, and approximately 9,320 deaths due to this disease.

Furthermore, an increase in awareness about the treatment of melanoma and improved healthcare facilities and infrastructure drives the market. In July 2014, the Office of the Surgeon General released The Surgeon General's Call to Action to Prevent Skin Cancer, establishing skin cancer prevention as a high priority for our nation. The Call to Action described prevention strategies that work and called on all community sectors to address skin cancer as a major public health problem. Since the release of the Call to Action, a growing community of partners at the national, state, and local levels has taken great strides to help prevent skin cancer in the United States. These factors are driving the growth of skin cancer drugs market in the forecast period.

Competitive Landscape

The skin cancer drugs market is highly competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd, Daiichi Sankyo Co., GlaxoSmithKline among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Skin Cancer Drugs Market globally. For instance, in January 2019, Merck's KEYTRUDA (pembrolizumab) received five new approvals in Japan, including adjuvant therapy for melanoma.

Amgen Inc.

Overview:

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses on human therapeutics and concentrates on innovating novel medicines based on cellular and molecular biology.

Product Portfolio:

IMLYGIC: IMLYGIC (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on skin or in lymph glands.

Why Purchase the Report?

  • Visualize the composition of the global skin cancer drugs market segmentation by cancer type, drug class, end user, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in global skin cancer drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global skin cancer drugs market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global skin cancer drugs Market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Skin Cancer Drugs Market- By Cancer Type

  • Melanoma
  • Non-melanoma

Basal cell carcinoma

Squamous cell carcinoma.

Merkel cell cancer

Global Skin Cancer Drugs Market- By Drug Class

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Other

Global Skin Cancer Drugs Market- By End-User

  • Hospital
  • Clinics
  • Cancer Research Institutes
  • Others

Global Skin Cancer Drugs Market- By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America
Product Code: DMPH4435

Table of Contents

1. Global Skin Cancer Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Skin Cancer Drugs Market- Market Definition and Overview

3. Global Skin Cancer Drugs Market- Executive Summary

  • 3.1. Market Snippet by Cancer Type
  • 3.2. Market Snippet by Drug Class
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Skin Cancer Drugs Market- Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of Skin Cancer
      • 4.1.1.2. Rising Awareness About Skin Cancer
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent Regulatory Framework
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Skin Cancer Drugs Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Skin Cancer Drugs Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Skin Cancer Drugs Market- By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type Segment
    • 7.1.2. Market Attractiveness Index, By Cancer Type Segment
  • 7.2. Melanoma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Non-melanoma
    • 7.3.1. Basal cell carcinoma
    • 7.3.2. Squamous cell carcinoma.
    • 7.3.3. Merkel cell cancer

8. Global Skin Cancer Drugs Market- By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy
  • 8.5. Other

9. Global Skin Cancer Drugs Market- By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User Segment
  • 9.2. Hospital *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Cancer Research Institutes
  • 9.5. Others

10. Global Skin Cancer Drugs Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Skin Cancer Drugs Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch

12. Global Skin Cancer Drugs Market- Company Profiles

  • 12.1. Amgen Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb Company
  • 12.3. F. Hoffmann-La Roche Ltd
  • 12.4. Sanofi S.A.-
  • 12.5. Merck & Co., Inc.
  • 12.6. Novartis AG -
  • 12.7. Sun Pharmaceutical Industries Ltd
  • 12.8. Daiichi Sankyo Co.
  • 12.9. GlaxoSmithKline

LIST NOT EXHAUSTIVE

13. Global Skin Cancer Drugs Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!